Moreover, high levels of eCBs (AEA, 2-AG) in the brain by inhibiting hydrolytic enzymes FAAH and MAGL are still a successful therapeutic option for controlling the immune response in AD and others brain disorders. Here, MGLL is linked to Alzheimer disease.